Do we need thrombin generation assays for monitoring anticoagulation?

被引：9

作者：

Dempfle, Carl-Erik ^{[1
]}

Borggrefe, Martin ^{[1
]}

机构：

[1] Univ Hosp Mannheim, Dept Med 1, D-68167 Mannheim, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2008年 / 100卷 / 02期

关键词：

D O I：

10.1160/TH08-07-0437

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：179 / 180

页数：2

共 14 条

[1] Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers [J].

Bijsterveld, NR ;

Moons, AH ;

Boekholdt, SM ;

van Aken, BE ;

Fennema, H ;

Peters, RJG ;

Meijers, JCM ;

Büller, HR ;

Levi, M .

CIRCULATION, 2002, 106 (20) :2550-2554

[2] Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease [J].

Brophy, DF ;

Martin, EJ ;

Gehr, TWB ;

Best, AM ;

Paul, K ;

Carr, ME .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :372-376

[3] The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies [J].

Brophy, Donald F. ;

Carr, Marcus E., Jr. ;

Martin, Erika J. ;

Venitz, Jurgen ;

Gehr, Todd W. B. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08) :887-894

[4] Low molecular weight heparin and bleeding in patients with chronic renal failure [J].

Crowther, Mark ;

Lim, Wendy .

CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (05) :409-413

[5] Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro [J].

Gatt, Alex ;

van Veen, Joost J. ;

Woolley, Anita M. ;

Kitchen, Steve ;

Cooper, Peter ;

Makris, Michael .

THROMBOSIS AND HAEMOSTASIS, 2008, 100 (02) :350-355

[6] Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation [J].

Gerotziafas, G. T. ;

Petropoulou, A. D. ;

Verdy, E. ;

Samama, M. M. ;

Elalamy, I. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (05) :955-962

[7] In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [J].

Gerotziafas, G. T. ;

Elalamy, I. ;

Depasse, F. ;

Perzborn, E. ;

Samama, M. M. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (04) :886-888

[8] Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma [J].

Gerotziafas, GT ;

Depasse, F ;

Chakroun, T ;

Van Dreden, P ;

Samama, MM ;

Elalamy, I .

BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (02) :149-156

[9] Calibrated automated thrombin generation measurement in clotting plasma [J].

Hemker, HC ;

Giesen, P ;

Al Dieri, R ;

Regnault, V ;

de Smedt, E ;

Wagenvoord, R ;

Lecompte, T ;

Béguin, S .

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) :4-15

[10] PROTAMINE NEUTRALIZATION OF INTRAVENOUS AND SUBCUTANEOUS LOW-MOLECULAR-WEIGHT HEPARIN (TINZAPARIN, LOGIPARIN(TM)) - AN EXPERIMENTAL INVESTIGATION IN HEALTHY-VOLUNTEERS [J].

HOLST, J ;

LINDBLAD, B ;

BERGQVIST, D ;

GARRE, K ;

NIELSEN, H ;

HEDNER, U ;

OSTERGAARD, PB .

BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (05) :795-803

← 1 2 →